Lipocine (LPCN) Enterprise Value (2016 - 2025)
Lipocine's Enterprise Value history spans 14 years, with the latest figure at -$15.1 million for Q3 2025.
- For Q3 2025, Enterprise Value rose 57.86% year-over-year to -$15.1 million; the TTM value through Sep 2025 reached -$15.1 million, up 57.86%, while the annual FY2024 figure was -$15.4 million, 60.67% up from the prior year.
- Enterprise Value reached -$15.1 million in Q3 2025 per LPCN's latest filing, up from -$17.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$15.1 million in Q3 2025 to a low of -$65.6 million in Q3 2022.
- Average Enterprise Value over 5 years is -$35.9 million, with a median of -$36.3 million recorded in 2022.
- Peak YoY movement for Enterprise Value: plummeted 191.02% in 2021, then surged 69.85% in 2023.
- A 5-year view of Enterprise Value shows it stood at -$44.7 million in 2021, then plummeted by 37.59% to -$61.5 million in 2022, then skyrocketed by 36.18% to -$39.2 million in 2023, then surged by 60.67% to -$15.4 million in 2024, then rose by 1.92% to -$15.1 million in 2025.
- Per Business Quant, the three most recent readings for LPCN's Enterprise Value are -$15.1 million (Q3 2025), -$17.9 million (Q2 2025), and -$36.1 million (Q1 2025).